Advertisement
New Zealand markets open in 6 hours 36 minutes
  • NZX 50

    11,590.47
    +19.25 (+0.17%)
     
  • NZD/USD

    0.6185
    +0.0019 (+0.32%)
     
  • ALL ORDS

    7,860.00
    -51.50 (-0.65%)
     
  • OIL

    76.76
    -0.28 (-0.36%)
     
  • GOLD

    2,040.80
    +1.00 (+0.05%)
     

Catalent (CTLT) Reports Q1 Earnings: What Key Metrics Have to Say

Catalent (CTLT) reported $982 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 3.9%. EPS of -$0.10 for the same period compares to $0.34 a year ago.

The reported revenue represents a surprise of +5.23% over the Zacks Consensus Estimate of $933.2 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +23.08%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Catalent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Organic Revenue Growth: -8% versus -10.3% estimated by two analysts on average.

  • Geographic Revenues- United States: $645 million compared to the $627.43 million average estimate based on two analysts.

  • Elimination of revenue: -$25 million versus -$24.43 million estimated by two analysts on average.

  • Revenue- International Other: $88 million versus the two-analyst average estimate of $70 million.

  • Revenue- Europe: $274 million versus $275.56 million estimated by two analysts on average.

  • Revenue- Biologics: $447 million compared to the $420.93 million average estimate based on four analysts.

  • Revenue- Pharma and Consumer Health: $535 million versus the four-analyst average estimate of $498.21 million.

  • Revenue- Pharma and Consumer Health- Manufacturing & commercial product supply: $335 million versus the two-analyst average estimate of $314.22 million.

  • Revenue- Pharma and Consumer Health- Development services & clinical supply: $200 million versus the two-analyst average estimate of $210.93 million.

  • Revenue- Manufacturing & commercial product supply Total: $616 million versus the two-analyst average estimate of $404.15 million.

  • Revenue- Development services & clinical supply Total: $366 million versus $547.08 million estimated by two analysts on average.

  • Revenue- Biologics- Manufacturing & commercial product supply: $281 million versus the two-analyst average estimate of $89.93 million.

View all Key Company Metrics for Catalent here>>>

Shares of Catalent have returned -12.1% over the past month versus the Zacks S&P 500 composite's +4.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Catalent, Inc. (CTLT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research